Inhibition of mouse mammary carcinoma development with doxorubicin in liposomes.
Monthly treatments with intravenous doxorubicin encapsulated in long circulating, sterically stabilized liposomes delayed the appearance of primary mammary carcinomas and reduced the final incidence from 49 in 50 untreated mice to 46 in 87 treated mice. No toxic side effects of the treatments were observed.